A study of New York’s court-ordered care for people with serious mental health conditions adds to the research on this type ...

Kennedy and Oz say Medicaid isn't being cut. But state Medicaid directors say new policies are likely to cause many people to ...

Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug ...

It is no longer possible to ask the FDA to keep pace with software development by doing the same reviews faster,” writes Dana ...

Six weeks after STAT reported that Eli Lilly granted a single 79-year-old patient special access to retatrutide, an ...

Two people have died in the cyclospora outbreak in Michigan in the first confirmed deaths in the U.S. related to the ...

Today, controversy over a regulator’s decision on AI scribes. Plus, a little more detail on Dexcom’s FDA pilot and an enlightening look at how scribes are working their way into medical education.

The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to ...

Medicare is removing flexibilities that have allowed "breakthrough" medical devices to leapfrog qualifications for extra ...

A White House proposal to subject research grants to political scrutiny meets at least a temporary roadblock in the Senate.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B ...